Rachel Bassett Allen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rachel Bassett Allen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Anita Yang
University of North Carolina Health Care, Chapel Hill, North Carolina, USA
3 shared publications - Mary Moss Chandran
Department of Pharmacy University of North Carolina Health Chapel Hill North Carolina USA
2 shared publications - Stephanie Shabanowitz
UNC Medical Center Chapel Hill North Carolina USA
2 shared publications - Anne M. Komé
Department of Pharmacy University of North Carolina Medical Center Chapel Hill North Carolina USA
1 shared publication - April L. Goley
Department of Medicine, University of North Carolina Medical Center, Chapel Hill, NC 27514, USA
1 shared publication - Bonnie Alexander
Department of Medicine, University of North Carolina Medical Center, Chapel Hill, NC 27514, USA
1 shared publication
Latest Publications
- 9 March 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (4) , e70123
Impact of Glucagon‐Like Peptide‐1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients
Introduction: Proteinuria is a marker of kidney dysfunction and increased cardiovascular mortality. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have shown significant cardiorenal benefits in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). However, the impact of GLP‐1 RAs on cardiorenal outcomes in kidney transplant recipients (KTRs) remains unclear. This study aims to assess the effect of GLP‐1 RA therapy on proteinuria and metabolic parameters in KTRs, with and without T2DM, 12 months following GLP‐1 RA initiation. Methods: A single‐center, retrospective study was conducted to evaluate the safety and efficacy of GLP‐1 RAs in adult KTRs from June 1, 2022 to December 31, 2023. Primary outcomes were changes in urine protein‐creatinine ratio (UPCR) and urine albumin‐to‐creatinine ratio (UACR) at 1, 3, 6, and 12 months after initiation of GLP‐1 RAs. Secondary outcomes assessed changes in estimated glomerular filtration (eGFR), body mass index (BMI), and hemoglobin A1c (A1C). Safety outcomes included cardiovascular hospitalizations, acute kidney injury, pancreatitis, and biopsy‐proven rejection within 12 months. Results: Forty KTRs received GLP‐1 RA therapy with a mean time to initiation of 4.3 months post‐transplant, and the majority of patients had T2DM (87.5%). Baseline UPCR and UACR were 0.86 and 669 mg/g, respectively. UPCR at 1, 3, and 6 months post‐initiation was 0.38 g/g, 0.37 g/g, and 0.30 g/g, respectively. UACR at 1, 3, and 6 months post‐initiation was 313 mg/g, 285 mg/g, and 234 mg/g, respectively. A 55% decrease from baseline in UPCR and UACR was observed at 1 month ( p = 0.070) and a 50% decrease from baseline was observed at 12 months ( p = 0.058), achieving UPCR of 0.43 g/g and UACR of 320 mg/g. A1C, eGFR, and BMI remained stable. Minimal safety events occurred. Conclusion: GLP‐1 RAs demonstrated clinically significant improvements in proteinuria as early as 1 month post‐initiation in KTRs. Proteinuria significantly improved from severely increased to moderately increased at 6 months following GLP‐1 RAs, with good tolerability. GLP‐1 RAs may offer renal benefits in KTRs with T2DM without compromising allograft function. Future studies should include closer monitoring of KTRs on immunosuppression with high gastrointestinal adverse effect profiles, and larger studies are needed to assess the long‐term impact of GLP‐1 RAs in KTRs irrespective of T2DM.
- 9 March 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (4) , e70123
Impact of Glucagon‐Like Peptide‐1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients
Introduction: Proteinuria is a marker of kidney dysfunction and increased cardiovascular mortality. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have shown significant cardiorenal benefits in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). However, the impact of GLP‐1 RAs on cardiorenal outcomes in kidney transplant recipients (KTRs) remains unclear. This study aims to assess the effect of GLP‐1 RA therapy on proteinuria and metabolic parameters in KTRs, with and without T2DM, 12 months following GLP‐1 RA initiation. Methods: A single‐center, retrospective study was conducted to evaluate the safety and efficacy of GLP‐1 RAs in adult KTRs from June 1, 2022 to December 31, 2023. Primary outcomes were changes in urine protein‐creatinine ratio (UPCR) and urine albumin‐to‐creatinine ratio (UACR) at 1, 3, 6, and 12 months after initiation of GLP‐1 RAs. Secondary outcomes assessed changes in estimated glomerular filtration (eGFR), body mass index (BMI), and hemoglobin A1c (A1C). Safety outcomes included cardiovascular hospitalizations, acute kidney injury, pancreatitis, and biopsy‐proven rejection within 12 months. Results: Forty KTRs received GLP‐1 RA therapy with a mean time to initiation of 4.3 months post‐transplant, and the majority of patients had T2DM (87.5%). Baseline UPCR and UACR were 0.86 and 669 mg/g, respectively. UPCR at 1, 3, and 6 months post‐initiation was 0.38 g/g, 0.37 g/g, and 0.30 g/g, respectively. UACR at 1, 3, and 6 months post‐initiation was 313 mg/g, 285 mg/g, and 234 mg/g, respectively. A 55% decrease from baseline in UPCR and UACR was observed at 1 month ( p = 0.070) and a 50% decrease from baseline was observed at 12 months ( p = 0.058), achieving UPCR of 0.43 g/g and UACR of 320 mg/g. A1C, eGFR, and BMI remained stable. Minimal safety events occurred. Conclusion: GLP‐1 RAs demonstrated clinically significant improvements in proteinuria as early as 1 month post‐initiation in KTRs. Proteinuria significantly improved from severely increased to moderately increased at 6 months following GLP‐1 RAs, with good tolerability. GLP‐1 RAs may offer renal benefits in KTRs with T2DM without compromising allograft function. Future studies should include closer monitoring of KTRs on immunosuppression with high gastrointestinal adverse effect profiles, and larger studies are needed to assess the long‐term impact of GLP‐1 RAs in KTRs irrespective of T2DM.
- Open Access
- 5 February 2026
- Published by Elsevier in AACE Endocrinology and Diabetes
- Vol. 13 (3) , 527-532
Assessing Primary Aldosteronism Screening Implementation and Interpretation in an Outpatient Internal Medicine Clinic: A Cohort Study
- 5 February 2026
- Published by Elsevier in AACE Endocrinology and Diabetes
- Vol. 13 (3) , 527-532
Open AccessAssessing Primary Aldosteronism Screening Implementation and Interpretation in an Outpatient Internal Medicine Clinic: A Cohort Study
- 4 November 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (11) , e70365
Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Proteinuria in Kidney Transplant Recipients
Introduction: Proteinuria is a marker of kidney dysfunction and increased cardiovascular mortality. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiorenal protection in chronic kidney disease, regardless of type 2 diabetes mellitus (T2DM) status. However, data evaluating SGLT2i impact on cardiorenal outcomes in kidney transplant recipients (KTRs) are limited. Methods: This single‐center, retrospective cohort study evaluated the safety and efficacy of SGLT2i therapy in adult KTRs transplanted between January 1, 2020 and December 31, 2023. Primary outcomes were changes in urine protein‐to‐creatinine ratio (UPCR) and urine albumin‐to‐creatinine ratio (UACR) at 1‐, 3‐, 6‐, and 12‐months post‐initiation. Secondary outcomes included changes in estimated glomerular filtration rate (eGFR), BMI, and hemoglobin A1c (HbA1c). Safety outcomes were cardiovascular hospitalization, acute kidney injury, urinary tract infection, and biopsy‐proven rejection within 12 months. Results: SGLT2i therapy was initiated in 77 KTRs, 524 days post‐transplant, predominantly in males (74.3%), African Americans (62.8%), and patients with T2DM (80.7%). Baseline UPCR and UACR were 0.387 g/g and 302.2 mg/g, respectively. No significant changes in UPCR, UACR, or eGFR were observed. Renal function was preserved at 12 months, with a transient decline at 1‐month that returned to baseline by 3 months. HbA1c and BMI remained stable. Few safety events occurred. Conclusions: In KTRs with moderate proteinuria, SGLT2i therapy was well tolerated with stable renal function over 12 months. A transient eGFR dip is consistent with patterns seen in non‐transplant populations. Absence of significant metabolic changes may reflect well‐controlled baseline parameters. Further studies are warranted to evaluate SGLT2i benefits in KTRs, especially in patients with higher grade proteinuria or early post‐transplant initiation.
- 4 November 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (11) , e70365
Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Proteinuria in Kidney Transplant Recipients
Introduction: Proteinuria is a marker of kidney dysfunction and increased cardiovascular mortality. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiorenal protection in chronic kidney disease, regardless of type 2 diabetes mellitus (T2DM) status. However, data evaluating SGLT2i impact on cardiorenal outcomes in kidney transplant recipients (KTRs) are limited. Methods: This single‐center, retrospective cohort study evaluated the safety and efficacy of SGLT2i therapy in adult KTRs transplanted between January 1, 2020 and December 31, 2023. Primary outcomes were changes in urine protein‐to‐creatinine ratio (UPCR) and urine albumin‐to‐creatinine ratio (UACR) at 1‐, 3‐, 6‐, and 12‐months post‐initiation. Secondary outcomes included changes in estimated glomerular filtration rate (eGFR), BMI, and hemoglobin A1c (HbA1c). Safety outcomes were cardiovascular hospitalization, acute kidney injury, urinary tract infection, and biopsy‐proven rejection within 12 months. Results: SGLT2i therapy was initiated in 77 KTRs, 524 days post‐transplant, predominantly in males (74.3%), African Americans (62.8%), and patients with T2DM (80.7%). Baseline UPCR and UACR were 0.387 g/g and 302.2 mg/g, respectively. No significant changes in UPCR, UACR, or eGFR were observed. Renal function was preserved at 12 months, with a transient decline at 1‐month that returned to baseline by 3 months. HbA1c and BMI remained stable. Few safety events occurred. Conclusions: In KTRs with moderate proteinuria, SGLT2i therapy was well tolerated with stable renal function over 12 months. A transient eGFR dip is consistent with patterns seen in non‐transplant populations. Absence of significant metabolic changes may reflect well‐controlled baseline parameters. Further studies are warranted to evaluate SGLT2i benefits in KTRs, especially in patients with higher grade proteinuria or early post‐transplant initiation.
- Open Access
- 11 October 2025
- Published by MDPI AG in Transplantology
- Vol. 6 (4) , 30
Should Early Hyperglycemia Be Considered a Risk Factor for Post-Transplant Diabetes Mellitus? Findings from a Retrospective Cohort Study in Kidney Transplant Recipients Without Diabetes Mellitus Prior to Transplant
Background: Post-transplant diabetes mellitus (PTDM) is a complication of kidney transplantation, but the impact of early hyperglycemia (EH) remains unclear. This study aimed to assess the incidence of PTDM in kidney transplant recipients (KTRs) who experienced EH compared to those who do not at 6 months post-transplant. Methods: A single-center, retrospective cohort study was conducted in adults who underwent kidney transplantation from 1 January 2019 to 25 May 2022. KTRs who developed EH were compared against those who did not. Results: The primary outcome was the difference in incidence of PTDM at 6 months. Secondary outcomes included rehospitalizations and infections within 6 months and PTDM, renal function, cardiovascular events, and graft and patient survival within 12 months. Two hundred and seventy-nine KTRs (EH, n = 204 vs. comparator, n = 75) were included. There were higher incidences of PTDM in the EH group compared to the comparator group at 6 months (11% vs. 1.4%, p = 0.012) and 12 months post-transplant (18.5% vs. 5.5%, p = 0.007). KTRs with EH had 8.9 times greater odds of developing PTDM (OR 8.9; 95% 1.2–67.3, p = 0.03) at 6 months. There was no significant difference found in other secondary outcomes. Conclusions: KTRs with EH had an increased incidence of developing PTDM.
- 11 October 2025
- Published by MDPI AG in Transplantology
- Vol. 6 (4) , 30
Open AccessShould Early Hyperglycemia Be Considered a Risk Factor for Post-Transplant Diabetes Mellitus? Findings from a Retrospective Cohort Study in Kidney Transplant Recipients Without Diabetes Mellitus Prior to Transplant
Background: Post-transplant diabetes mellitus (PTDM) is a complication of kidney transplantation, but the impact of early hyperglycemia (EH) remains unclear. This study aimed to assess the incidence of PTDM in kidney transplant recipients (KTRs) who experienced EH compared to those who do not at 6 months post-transplant. Methods: A single-center, retrospective cohort study was conducted in adults who underwent kidney transplantation from 1 January 2019 to 25 May 2022. KTRs who developed EH were compared against those who did not. Results: The primary outcome was the difference in incidence of PTDM at 6 months. Secondary outcomes included rehospitalizations and infections within 6 months and PTDM, renal function, cardiovascular events, and graft and patient survival within 12 months. Two hundred and seventy-nine KTRs (EH, n = 204 vs. comparator, n = 75) were included. There were higher incidences of PTDM in the EH group compared to the comparator group at 6 months (11% vs. 1.4%, p = 0.012) and 12 months post-transplant (18.5% vs. 5.5%, p = 0.007). KTRs with EH had 8.9 times greater odds of developing PTDM (OR 8.9; 95% 1.2–67.3, p = 0.03) at 6 months. There was no significant difference found in other secondary outcomes. Conclusions: KTRs with EH had an increased incidence of developing PTDM.